4:54 PM
 | 
Apr 12, 2013
 |  BC Extra  |  Clinical News

Iroko reports Phase III data for submicron diclofenac

Iroko Pharmaceuticals LLC (Philadelphia, Pa.) said thrice-daily lower dose submicron diclofenac met the primary endpoint of reducing mean WOMAC pain subscale scores from baseline to week 12 vs. placebo in a Phase III trial to treat osteoarthritis...

Read the full 171 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >